Lowest Price Guaranteed
From USD
949
Published
July 2016
Pages
0
View Count
1205
Available on request
After years of research tracing back to the 18th century, a gamut of novel therapies namely, CAR-T, TCR and TIL therapies, have finally reached a point of maturity. These promising therapeutic strategies, developed under the banner of T-cell immunotherapies, are set to hit the market in the near future.T-cells, also named as the soldiers of the immune system, are featured with specificity and functionally combat infections, cancerous cells and other foreign entities. High therapeutic potential and favorable clinical outcomes outweigh the challenges such as high cost, tedious manufacturing and ethical concerns serving as the roadblocks to the progress of the therapy.
With no marketed products, this emerging field is still in its infancy. Research institutions, through investment of time, expertise and effort, have played a critical role in maturing the design and development of novel CAR-Ts, TCRs and TILs. Post the initial research, industry players have collaborated with non-industry participants to fund the clinical and commercial development of these products. Some late stage products that have emerged out of such collaborations include CTL-019 (Novartis/University of Pennsylvania/The Children’s Hospital of Philadelphia), JCAR017 (Juno Therapeutics/Seattle Children’s Hospital), KTE-C19 and HPV-16 E6 TCR (Kite Pharma/National Cancer Institute), CD19-CAR (Takara Bio/Jichi Medical University) and LN-144 (Lion Biotechnologies/National Cancer Institute).
The primary objective of this report is to capture details on the various clinical trials that are currently underway in the field of T-cell Immunotherapy. We have identified a number of T-cell Immunotherapy products and clinical trials that are either being conducted or planned to be conducted for each of these products. For each specific product, we have provided the following information:
For each specific trial, we have provided the following information:
The above information has also been presented in the form a dashboard to provide a high level quick overview of the ongoing activity in this space.
In addition to the clinical trial details, the report also provides the following:
1. Market Overview
2. Dashboard: Pipeline and Trial Analysis
3. CAR-T Clinical Development: Trial Details
4. TCR Clinical Development: Trial Details
5. TIL Clinical Development: Trial Details
6. Market Forecast: Assumptions
7. Market Forecast, 2015-2030
8. Preclinical Development
9. Inclusion / Exclusion Criteria
10. Abbreviations
Pipeline and Trial Details
Figure 1 T-cell Immunotherapy Products in Clinical Development: Distribution by Type of Therapy
Figure 2 T-cell Immunotherapy Trialsin Clinical Development: Distribution by Type of Therapy
Figure 3 T-cell Immunotherapy Products in Clinical Development: Distribution by Phase of Development
Figure 4 T-cell Immunotherapy Products in Clinical Development: Distribution by Phase of Development and Type of Therapy
Figure 5 T-cell Immunotherapy Products in Clinical Development: Distribution by Therapeutic Area
Figure 6 T-cell Immunotherapy Products in Clinical Development: Distribution by Therapeutic Area and Type of Therapy
Figure 7 T-cell Immunotherapy Products in Clinical Development: Distribution by Target in the CAR-T Market
Figure 8 T-cell Immunotherapy Products in Clinical Development: Distribution by Targets in the TCR Market
Figure 9 T-cell Immunotherapy Products in Clinical Development: Distribution by Industrial Developers for CAR-T Therapy
Figure 10 T-cell Immunotherapy Products in Clinical Development: Distribution by Industrial Developers for TCR Therapy
Figure 11 T-cell Immunotherapy Trials in Clinical Development: Distribution by Phase of Development
Figure 12 T-cell Immunotherapy Trials in Clinical Development: Distribution by Phase of Development and Type of Therapy
Figure 13 T-cell Immunotherapy Trials in Clinical Development: Distribution by Therapeutic Area
Figure 14 T-cell Immunotherapy Trials in Clinical Development: Distribution by Therapeutic Area and Type of Therapy
Figure 15 T-cell Immunotherapy Trials in Clinical Development: Distribution by Trial Status
Figure 16 T-cell Immunotherapy Trials in Clinical Development: Distribution by Trial Status and Type of Therapy
Figure 17 T-cell Immunotherapy Trials in Clinical Development: Distribution by Sponsorship
Figure 18 T-cell Immunotherapy Trials in Clinical Development: Distribution by Sponsorship and Type of Therapy
Figure 19 T-cell Immunotherapy Trials in Clinical Development: Distribution by Region
Figure 20 T-cell Immunotherapy Trials in Clinical Development: Distribution by Region and Type of Therapy
Figure 21 T-cell Immunotherapy Trials in Clinical Development: Distribution by G7 Countries
Figure 22 T-cell Immunotherapy Trials in Clinical Development: Distribution by G7 Countries and Type of Therapy
Market Forecast Analysis
Figure A T-cell Immunotherapy Market Forecast, 2015-2030
Figure B T-cell Immunotherapy Market, Share of Sub-segments: Base Scenario 2020, 2025 and 2030 (USD Million
Pipeline Details
Table 1 CAR-T Clinical Development: Pipeline Details
Table 2 TCR Clinical Development: Pipeline Details
Table 3 TIL Clinical Development: Pipeline Details
Table 4 Preclinical Development
Market Forecast Analysis
Table A Market Forecast: Assumptions
The following companies and organisations have been mentioned in the report:
Discounts available for multiple report purchases
sales@rootsanalysis.com
.png)
.jpg)
.png)
.png)
.jpg)
.jpg)
.jpg)
